Jubilant Pharmo

48
Sell
  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE700A01033
  • NSEID: JUBLPHARMA
  • BSEID: 530019
INR
1,065.00
-4.2 (-0.39%)
BSENSE

Dec 05

BSE+NSE Vol: 17.29 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationProfit and Loss Results
Results Snapshot
Figures in Cr
Consolidated - Profit And Loss Results
Mar'25
Mar'24
Mar'23
Mar'22
Mar'21
Mar'20
No of Months
12
12
12
12
12
12
Operating Income
7,234.00
6,702.00
6,281.00
6,130.00
6,098.00
5,975.00
Less :Inter divisional transfers
0.00
0.00
0.00
0.00
0.00
0.00
Less: Excise
0.00
0.00
0.00
0.00
0.00
0.00
Net Sales
7,234.00
6,702.00
6,281.00
6,130.00
6,098.00
5,975.00
Expenditure (Ex Depriciation)
Stock Adjustments
34.00
78.00
-40.00
-62.00
19.00
-137.00
Raw Materials Consumed
2,282.00
2,062.00
1,918.00
1,550.00
1,516.00
1,592.00
Power & Fuel Cost
154.00
148.00
166.00
134.00
105.00
112.00
Employee Cost
2,267.00
2,216.00
2,166.00
2,043.00
1,922.00
1,843.00
Operating Expenses
528.00
506.00
568.00
552.00
440.00
353.00
General and Administration Expenses
-1.00
-1.00
-1.00
-1.00
-1.00
-1.00
Selling and Distribution Expenses
205.00
214.00
161.00
209.00
177.00
194.00
Cost of Software developments
0.00
0.00
0.00
0.00
0.00
0.00
Miscellaneous Expenses
57.00
67.00
72.00
89.00
113.00
32.00
Expenses Capitalised
0.00
0.00
0.00
0.00
0.00
0.00
Total Expenditure
6,060.00
5,802.00
5,505.00
4,973.00
4,702.00
4,427.00
Operating Profit (PBDIT) excl Other Income
1,173.00
900.00
776.00
1,156.00
1,396.00
1,547.00
Other Income
56.00
68.00
38.00
11.00
17.00
37.00
Operating Profit (PBDIT)
1,230.00
969.00
814.00
1,167.00
1,414.00
1,585.00
Interest
240.00
272.00
188.00
145.00
184.00
199.00
Profit before Depriciation and Tax
990.00
697.00
626.00
1,022.00
1,230.00
1,385.00
Depreciation
368.00
381.00
554.00
381.00
348.00
339.00
Profit Before Taxation & Exceptional Items
621.00
315.00
72.00
640.00
881.00
1,045.00
Exceptional Income / Expenses
0.00
0.00
0.00
0.00
0.00
0.00
Profit Before Tax
980.00
170.00
27.00
630.00
871.00
1,012.00
Provision for Tax
144.00
97.00
92.00
217.00
297.00
335.00
Profit After Tax
836.00
48.00
-77.00
422.00
562.00
677.00
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
Adj to Profit After Tax
0.00
0.00
0.00
0.00
0.00
0.00
Profit Balance B/F
4,539.00
4,536.00
4,685.00
4,317.00
3,844.00
3,102.00
Profit Available for appropriations
5,379.00
4,613.00
4,624.00
4,731.00
4,418.00
3,780.00
Appropriations
5,379.00
4,613.00
4,624.00
4,731.00
4,418.00
3,780.00
Equity Dividend (%)
500.00%
500.00%
500.00%
500.00%
500.00%
500.00%
Earnings Per Share
52.99
4.87
-3.83
26.00
52.48
56.39
Profit And Loss Analysis Highlights
stock-summary

Net Sales

YoY Growth in year ended Mar 2025 is 7.93% vs 6.71% in Mar 2024

stock-summary

Operating Profit (PBDIT) excl Other Income

YoY Growth in year ended Mar 2025 is 30.30% vs 16.05% in Mar 2024

stock-summary

Interest

YoY Growth in year ended Mar 2025 is -11.75% vs 44.69% in Mar 2024

stock-summary

Profit After Tax

YoY Growth in year ended Mar 2025 is 1,621.81% vs 162.95% in Mar 2024

Compare Profit and Loss Results of Jubilant Pharmo
Markets Mojo
Figures in Cr
consolidated - Profit And Loss Results
Markets Mojo
Markets Mojo
Change(INR)
Change(%)
No of Months
12
12
Operating Income
7,234.00
6,672.00
562.00
8.42%
Less :Inter divisional transfers
0.00
0.00
0.00
0%
Less: Excise
0.00
0.00
0.00
0%
Net Sales
7,234.00
6,672.00
562.00
8.42%
Expenditure (Ex Depriciation)
Stock Adjustments
34.00
-289.00
323.00
111.76%
Raw Materials Consumed
2,282.00
2,083.00
199.00
9.55%
Power & Fuel Cost
154.00
179.00
-25.00
-13.97%
Employee Cost
2,267.00
1,562.00
705.00
45.13%
Operating Expenses
528.00
431.00
97.00
22.51%
General and Administration Expenses
-1.00
-1.00
0.00
0.00%
Selling and Distribution Expenses
205.00
1,064.00
-859.00
-80.73%
Cost of Software developments
0.00
0.00
0.00
0%
Miscellaneous Expenses
57.00
46.00
11.00
23.91%
Expenses Capitalised
0.00
0.00
0.00
0%
Total Expenditure
6,060.00
5,663.00
397.00
7.01%
Operating Profit (PBDIT) excl Other Income
1,173.00
1,008.00
165.00
16.37%
Other Income
56.00
42.00
14.00
33.33%
Operating Profit (PBDIT)
1,230.00
1,050.00
180.00
17.14%
Interest
240.00
78.00
162.00
207.69%
Profit before Depriciation and Tax
990.00
972.00
18.00
1.85%
Depreciation
368.00
278.00
90.00
32.37%
Profit Before Taxation & Exceptional Items
621.00
693.00
-72.00
-10.39%
Exceptional Income / Expenses
0.00
0.00
0.00
0%
Profit Before Tax
980.00
707.00
273.00
38.61%
Provision for Tax
144.00
125.00
19.00
15.20%
Profit After Tax
836.00
581.00
255.00
43.89%
Extraordinary Items
0.00
0.00
0.00
0%
Adj to Profit After Tax
0.00
0.00
0.00
0%
Profit Balance B/F
4,539.00
4,027.00
512.00
12.71%
Profit Available for appropriations
5,379.00
4,610.00
769.00
16.68%
Appropriations
5,379.00
4,610.00
769.00
16.68%
Equity Dividend (%)
500%
550%
-50.00
Earnings Per Share
52.99
29.68
23.31
78.54%
Profit And Loss - Net Sales
Net Sales 7,234.50 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is 7.93% vs 6.71% in Mar 2024

Profit And Loss - Operating Profit (PBDIT)
Operating Profit (PBDIT) 1,173.70 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is 30.30% vs 16.05% in Mar 2024

Profit And Loss - Interest
Interest 240.30 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is -11.75% vs 44.69% in Mar 2024

Profit And Loss - Profit After Tax
Profit After Tax 836.80 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is 1,621.81% vs 162.95% in Mar 2024